Does Pregnancy Increase Cancer Risk?

Pregnancy both raises and lowers cancer risk, depending on the cancer type and the time frame you look at. For breast cancer, the most-studied example, there is a temporary increase in risk for roughly a decade after giving birth, followed by a lasting protective effect that persists for the rest of a woman’s life. For ovarian and endometrial cancers, the picture is simpler: pregnancy lowers risk. For melanoma, the evidence leans toward no meaningful connection at all. The relationship between pregnancy and cancer resists a single headline, but the biology behind it is surprisingly well mapped.

The Dual Effect on Breast Cancer

A landmark study pooling data from three Scandinavian cancer registries found that women who had given birth once were at higher risk of breast cancer than women who had never been pregnant for up to 15 years after delivery, and at lower risk thereafter.¹ The elevated risk peaked around five years after a first birth, with an odds ratio of about 1.5 compared to women who had never given birth.² In practical terms, that means a roughly 50 percent higher relative risk during the peak years, which then gradually fades and eventually reverses into protection.

Women who had a second pregnancy showed a smaller and shorter-lived bump in risk from that pregnancy, because the long-term protective effect of their first birth was already working in the background.¹ And the more children a woman has, the stronger the long-term protection becomes. A Nordic meta-analysis of eight studies found that for every two births, breast cancer risk dropped by about 16 percent over the long run.³

So the answer for breast cancer is genuinely both: pregnancy temporarily raises risk and permanently lowers it. Whether you are currently in the elevated-risk window or the protective window depends on how recently you gave birth.

Why the First Decade After Birth Is Risky

After breastfeeding ends, the breast goes through a dramatic remodeling process called involution. The milk-producing tissue shrinks back, and the breast returns to its pre-pregnancy architecture. That remodeling looks, at a cellular level, a lot like wound healing. Immune cells flood in, the tissue matrix gets broken down and rebuilt, and new blood and lymphatic vessels form. These are all things that happen to be very useful to a tumor trying to establish itself.⁴

Research on this window has identified specific markers of the problem. The involuting breast ramps up collagen remodeling, matrix-degrading enzymes, and immune cells that suppress the anti-tumor response. These features overlap heavily with what is seen inside aggressive breast tumors.⁵ Women diagnosed with breast cancer within about ten years of their most recent birth tend to have more aggressive disease and a higher risk that it will spread, compared with women who have never been pregnant or were diagnosed well outside that window.⁵

In rodent models, the involuting mammary gland is enough on its own to make implanted tumor cells grow faster, invade more deeply, and metastasize more readily. Interestingly, treating rodents with common anti-inflammatory drugs during involution reduced those tumor-promoting effects, which suggests the immune environment of involution is a key driver rather than something inherent to the breast tissue itself.⁶

Why Early Pregnancy Protects

The long-term protective side of the equation is thought to come from changes to breast cells triggered by a full-term pregnancy, particularly the first one. Pregnancy hormones push breast stem cells toward a more mature, differentiated state. Once those cells have completed the cycle of pregnancy, lactation, and involution, they are less susceptible to the mutations that lead to cancer later in life.⁷

Age at first birth turns out to be far more important than total number of pregnancies. A large international study estimated that women who had their first child before age 18 had only about one-third the lifetime breast cancer risk of women who waited until 35 or later.⁸ Subsequent births after the first, even at a young age, added little extra protection. The same study noted that the well-known link between having more children and lower breast cancer risk is largely explained by early first birth, because women who start young tend to have more children overall.⁸

The Nordic meta-analysis put numbers on the flip side: women who had never given birth had about a 30 percent higher risk of breast cancer compared with women who had, and women whose first birth came after age 35 had about a 40 percent higher risk compared with those who gave birth before 20.³ Increasing age at first and second births was also associated with higher long-term risk, while age at later births did not seem to matter.⁹

Ovarian and Endometrial Cancers

For cancers of the uterine lining and the ovaries, the story is more straightforward: pregnancy is protective, and the mechanism kicks in remarkably early. A large Danish nationwide cohort study found that even pregnancies ending very early, including induced abortions, were associated with reduced endometrial cancer risk. The researchers concluded that the risk reduction could be explained by a biological process that occurs within the first weeks of pregnancy.¹⁰

For ovarian cancer, a separate 50-year Danish cohort study found that any type of pregnancy reduced risk, and there was no difference whether the pregnancy ended in childbirth, spontaneous miscarriage, or induced abortion.¹¹ The protective effect seems to come from interrupting ovulation and from hormonal shifts that begin almost immediately after conception. Because each pregnancy pauses ovulation for months, women with more pregnancies accumulate fewer ovulatory cycles over a lifetime, and that is one of the strongest known protective factors for ovarian cancer.

Melanoma and Pregnancy

Pregnant women often notice changes in moles, which has fueled a long-running worry that pregnancy might promote melanoma. The concern makes intuitive sense: pregnancy involves surges of estrogen and other hormones that stimulate pigment cells. But the epidemiological evidence has consistently failed to confirm it. A pooled analysis of ten case-control studies with over 5,500 women found no association between melanoma risk and pregnancy. If anything, women with five or more births had slightly lower melanoma risk than women who had never been pregnant.¹²

A more recent matched cohort study involving over 850,000 women per group reached the same conclusion: pregnancy was not associated with increased risk of invasive melanoma or melanoma in situ, and no significant differences appeared at any body site.¹³ One case-control study did find that women whose moles visibly changed during a recent pregnancy had about a threefold increase in melanoma risk, but that was based on small numbers.¹⁴ The takeaway is that pregnancy itself does not appear to be an independent risk factor for melanoma, though changing moles during pregnancy still deserve attention from a dermatologist.

Mouse studies have shown a different picture, with pregnancy-associated increases in lymphatic vessel growth inside tumors that led to more metastasis.¹⁵ That does not appear to translate cleanly to human outcomes, but it is a reminder that the relationship between a pregnant immune system and an existing cancer may differ from the question of whether pregnancy causes new cancers to form in the first place.

Cancers That Only Arise From Pregnancy

There is one category of cancer that is, by definition, caused by pregnancy: gestational trophoblastic disease. This is a spectrum of conditions in which the cells that would normally form the placenta grow abnormally. The mildest form is a hydatidiform mole, sometimes called a molar pregnancy, in which a fertilized egg develops into a mass of abnormal tissue instead of a viable embryo. Most molar pregnancies are benign and resolve with treatment, but a small percentage progress to gestational trophoblastic neoplasms, including choriocarcinoma.¹⁶

Choriocarcinoma is a highly malignant cancer that invades the uterine wall and tends to spread early through the bloodstream. It can arise from a molar pregnancy, from a normal pregnancy, or even from an ectopic pregnancy.¹⁶ The good news is that it is extraordinarily responsive to chemotherapy. Cure rates, even for metastatic disease, are well above 90 percent in most settings. But it is worth knowing that this is a real, if rare, cancer that exists solely because of pregnancy.

Fetal Cells That Stick Around

During pregnancy, a small number of fetal cells cross the placenta and take up permanent residence in the mother’s body. This phenomenon, called fetal microchimerism, means that most women who have been pregnant carry cells from their children for decades afterward. These fetal cells have stem-cell properties and have been found in a variety of maternal tissues, including the breast, thyroid, liver, and skin.¹⁷

The role of these cells in cancer is an active area of research and has produced a split picture. Fetal cells show up less frequently in women with breast cancer and lymphoma, suggesting they may help the immune system keep those cancers in check.¹⁸ One prominent hypothesis is that because fetal cells are genetically semi-foreign, they provide a form of extra immune surveillance: the mother’s immune system stays slightly more activated against abnormal cells, and that watchfulness catches some cancers early.¹⁹ But fetal cells have also been found at higher rates in women with colon cancer and certain autoimmune diseases, which complicates the protective narrative.¹⁸ The research is nowhere near settled enough to say whether these leftover fetal cells are net helpers or net troublemakers. It is possible they are both, depending on the tissue and the cancer type.

The Immune Parallel Between Pregnancy and Tumors

One of the more provocative findings in this field is that pregnancy and cancer use remarkably similar strategies to avoid immune destruction. A developing placenta is, from the immune system’s point of view, a mass of half-foreign tissue that needs to embed itself in the uterine wall, build its own blood supply, and suppress the local immune response so the mother’s body does not reject it. Cancer does all the same things.²⁰

Both the placenta and tumors rely on similar shifts in immune regulation, including the expansion of immune cells that suppress the body’s attack response. This shared biology does not mean pregnancy “is” cancer or that it directly triggers cancer. It means the evolutionary toolkit that makes pregnancy possible overlaps with the toolkit that cancers exploit.²¹ One evolutionary analysis took this further, finding that across mammalian species, the more deeply the placenta invades maternal tissue, the more vulnerable that species is to cancer in general. Humans have deeply invasive placentas and relatively high cancer vulnerability compared to animals with more superficial placentation.²²

Treating Cancer During Pregnancy

When cancer is diagnosed during pregnancy, one of the first questions is whether treatment can begin without waiting for delivery. The short answer is that many standard chemotherapy regimens can be given after the first trimester with relatively low risk to the fetus. Most guidelines place the safe window at roughly 12 to 14 weeks of gestation onward, with chemotherapy typically stopped a few weeks before the expected delivery date to allow the mother’s and baby’s bone marrow to recover.²³²⁴

The reason this works is partly pharmacological. Although many chemotherapy drugs have properties that should theoretically let them cross the placenta easily, studies in primates show the actual concentrations reaching the fetus are substantially lower than those in the mother’s bloodstream. Depending on the drug, placental transfer ranges from negligible to moderate, but it is always meaningfully diluted.²⁵

Imaging during pregnancy requires more care. Ultrasound and MRI are considered first-line options because they don’t involve radiation. CT scans and nuclear imaging can be performed when necessary but only when the clinical benefit clearly outweighs the fetal risk, and the cumulative fetal radiation exposure should be kept below 100 milligray.²⁶

What Happens to Children Exposed to Chemotherapy in the Womb

Follow-up studies on children whose mothers received chemotherapy during pregnancy have been mostly reassuring. A cohort tracked to a median age of seven years found that most children exposed to chemotherapy in utero were growing normally, with no significant treatment-related health problems. The rate of congenital abnormalities in the cohort matched the national average of about 3 percent.²⁷

A separate study looking at behavior, hearing, heart function, and general health in children whose mothers received prenatal chemotherapy found measurements that matched the general population across the board. Cardiac dimensions and function were within normal ranges. The researchers did flag subtle changes in some cardiac and cognitive measures that warranted longer follow-up, but the association that stood out most was not with chemotherapy itself but with premature delivery. Prematurity, which is more common in pregnancies complicated by cancer treatment, was linked to impaired cognitive development.²⁸

A more recent population-based cohort study found a modest increase in severe neonatal morbidity or mortality among babies exposed to chemotherapy in utero, but when the researchers dug into the mechanism, preterm birth accounted for essentially all of the observed risk. There was no increase in neurodevelopmental disorders or complex chronic conditions.²⁹ The consistent message is that the chemotherapy itself is not the primary hazard to the child; the bigger danger comes from delivering too early to avoid the chemotherapy.

Fertility Treatments and Cancer Risk

Women who use fertility drugs sometimes worry that the hormonal stimulation involved could increase cancer risk. The picture here is complicated by the fact that the women using these treatments often differ from the general population in important ways, including the underlying reason they needed fertility treatment in the first place. A large registry study found a small overall increase in cancer risk among women exposed to the fertility drug clomiphene citrate, but the elevated risks were concentrated in women who remained childless after treatment. Among women treated with assisted reproductive technology who went on to have children, the overall cancer risk was not significantly different from the general population.³⁰

For breast cancer specifically, a large Dutch study comparing IVF-treated women to the general population found no increased risk: the standardized incidence ratio was essentially 1.0, and the cumulative incidence of breast cancer by age 55 was nearly identical between IVF-treated and untreated women.³¹ The ovarian cancer concern deserves more attention, though: that same registry study found a roughly two-and-a-half-fold increase in ovarian cancer risk among nulliparous women who had used clomiphene citrate.³⁰ Whether that reflects the drug exposure, the underlying infertility, or some combination remains an open question.

Why Humans May Be Uniquely Vulnerable

A broader evolutionary lens puts the pregnancy-cancer connection in an unexpected light. A study comparing placental biology across mammalian species found that the degree to which the placenta invades maternal tissue during pregnancy correlates with that species’ overall vulnerability to malignant cancer. Species with deeply invasive placentas, like humans, tend to have higher rates of cancer. Species with more superficial placentas tend to be more cancer-resistant.²²

The researchers proposed that the same tissue properties that allow a human placenta to embed deeply into the uterine wall — essentially, the body’s tolerance for invasion — also make human tissues more permissive to cancer cells trying to spread. This does not mean pregnancy causes cancer in any direct sense. It means that the evolutionary bargain humans struck for deep placentation, which provides an efficient nutrient supply to a large-brained fetus, comes with a side effect: our tissues are inherently more penetrable by invasive cells, whether those cells belong to a placenta or a tumor. It is a trade-off baked into our biology, not a risk that can be avoided through any individual decision about reproduction.

1
PubMed. Transient increase in the risk of breast cancer after giving birth
2
PubMed. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden)
3
PubMed. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries
4
PubMed Central. Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?
5
PubMed Central. Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms
6
PubMed Central. Mammary gland involution as an immunotherapeutic target for postpartum breast cancer
7
PubMed. Pregnancy and breast cancer: the other side of the coin
8
PubMed Central. Age at first birth and breast cancer risk
9
British Journal of Cancer. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects
10
BMJ. Pregnancy duration and endometrial cancer risk: nationwide cohort study
11
PubMed Central. Pregnancy duration and ovarian cancer risk: A 50‐year nationwide cohort study
12
PubMed. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues
13
PubMed. Pregnancy and risk of melanoma: a matched retrospective cohort study
14
American Journal of Epidemiology. Reproductive Risk Factors for Cutaneous Melanoma in Women: A Case-Control Study
15
PubMed Central. Pregnancy promotes melanoma metastasis through enhanced lymphangiogenesis
16
PubMed. Trophoblastic disease and choriocarcinoma
17
PubMed Central. Fetal microchimerism and cancer
18
PubMed Central. Fetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human Health
19
Trends in Molecular Medicine. Fetomaternal microchimerism: The sculptural memory of pregnancy in the maternal body
20
PubMed Central. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents
21
PubMed Central. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
22
PubMed Central. Evolution of placental invasion and cancer metastasis are causally linked
23
PubMed. Patient-Centered Care in the Management of Cancer During Pregnancy
24
International Journal of Gynecological Cancer. Management of pregnancy in women with cancer
25
PubMed Central. Chemotherapy against cancer during pregnancy A systematic review on neonatal outcomes
26
PubMed Central. Imaging modalities in pregnant cancer patients
27
PubMed Central. Outcomes of children exposed in utero to chemotherapy for breast cancer
28
The Lancet Oncology. Protective effects of prenatal chemotherapy on maternal cancer
29
JNCI: Journal of the National Cancer Institute. Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study
30
PubMed Central. Cancer Risk in Women Treated with Fertility Drugs According to Parity status – A Registry-based Cohort Study
31
JAMA. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer